StockData
Climb Bio, Inc. logo

Climb Bio, Inc. (CLYM) stock

CLYMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$9.78−0.16 (-1.61%)

Close on Nov 17, 2026Market cap $561.73MP/E –Yield –

Climb Bio total assets

Total assets on the balance sheet at the end of each period.

Climb Bio's total assets was $246.29M at Jun 30, 2026. For fiscal 2025 it was $167.74M, down 22.8% from the year before. The highest annual figure on record is $217.19M in fiscal 2024.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$167.74M-22.8%
FY2024Dec 31, 2024$217.19M+96.6%
FY2023Dec 31, 2023$110.47M-18.2%
FY2022Dec 31, 2022$134.99M-22.1%
FY2021Dec 31, 2021$173.24M+603.3%
FY2020Dec 31, 2020$24.63M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$246.29M+28.0%
Q1 FY2026Mar 31, 2026$152.37M-24.1%
Q4 FY2025Dec 31, 2025$167.74M-22.8%
Q3 FY2025Sep 30, 2025$182.30M-18.0%
Q2 FY2025Jun 30, 2025$192.39M-14.9%
Q1 FY2025Mar 31, 2025$200.74M+83.6%
Q4 FY2024Dec 31, 2024$217.19M+96.6%
Q3 FY2024Sep 30, 2024$222.20M+97.1%
Q2 FY2024Jun 30, 2024$226.02M+94.4%
Q1 FY2024Mar 31, 2024$109.33M-10.4%
Q4 FY2023Dec 31, 2023$110.47M-18.2%
Q3 FY2023Sep 30, 2023$112.74M-20.0%
Q2 FY2023Jun 30, 2023$116.27M-22.5%
Q1 FY2023Mar 31, 2023$122.09M-24.8%
Q4 FY2022Dec 31, 2022$134.99M-22.1%
Q3 FY2022Sep 30, 2022$140.86M-22.7%
Q2 FY2022Jun 30, 2022$150.11M+39.5%
Q1 FY2022Mar 31, 2022$162.42M+559.4%
Q4 FY2021Dec 31, 2021$173.24M–
Q3 FY2021Sep 30, 2021$182.25M–
Q2 FY2021Jun 30, 2021$107.63M–
Q4 FY2020Dec 31, 2020$24.63M–

More Climb Bio figures

See a number that looks wrong?